CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis.

Shyng-Shiou F YuanYuk-Kwan ChenStephen Chu-Sung HuYa-Ling HsuChun-Hao TsaiTsung-Chen ChiWan-Ling HuangPei-Wen HsiehShyng-Shiou F Yuan

Published in: Cancer chemotherapy and pharmacology (2017)

CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo, and has the potential to be further developed into an anti-ovarian cancer drug clinically.

Keyphrases

dna damage
oxidative stress
cell proliferation
dna repair
emergency department
human health